In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Petrelintide | Synthetic analog Semaglutide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 22 | 4,624 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 12 (12 in people) | 1,224 (1,221 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 12 · 6 active | 663 · 284 active124 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 27 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Petrelintide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weight | 77 | 969954105 |
| Adverse events |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Ozempic says: “Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes; reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; reduce the risk of sustained eGFR decline…”
22 |
7757723 |
| Gastrointestinal adverse eventsGastrointestinal | 99 | 345345 |
|---|
| MortalityWhole body | 11 | 1041031 |
|---|
| PharmacokineticsPharmacology | 33 | 93894 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Semaglutide differs from Glucagon-like peptide 1 (7-37) at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Petrelintide | Semaglutide |
|---|---|---|
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in % | −9.8% Bodyweight change from baseline at 28 weeks · petrelintide 5·0 mg Placebo: −1.7% Dose studied: 5·0 mg once weekly28 weeksn = 1642026 | −18.7% Mean bodyweight change · semaglutide 7.2 mg Placebo: −3.9% Dose studied: 7.2 mg once weekly72 weeksn = 1,2062025 |
| Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in % | 20% Nausea incidence · petrelintide (79 of 404) Placebo (5 participants): 6% n = 4852026 | 43.9% Nausea incidence · semaglutide 2.4 mg |
−9.8%
Bodyweight change from baseline at 28 weeks · petrelintide 5·0 mg
Placebo: −1.7%
Dose studied: 5·0 mg once weekly28 weeksn = 1642026
−18.7%
Mean bodyweight change · semaglutide 7.2 mg
Placebo: −3.9%
Dose studied: 7.2 mg once weekly72 weeksn = 1,2062025
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Petrelintide | Semaglutide |
|---|---|---|
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in h·nmol/l | No comparable result 3 randomized-trial results measure it in another way or another unit. | 233 h·nmol/L AUC0-24h,sema,SS · 3 mg oral semaglutide Dose studied: 3 mg12 weeksn = 32 |
20%
Nausea incidence · petrelintide (79 of 404)
Placebo (5 participants): 6%
n = 4852026
43.9%
Nausea incidence · semaglutide 2.4 mg
Dose studied: 2.4 mg once weekly68 weeksn = 3,3792022
| Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in % | No comparable result 2 randomized-trial results measure it in another way or another unit. | 86.2% Adverse events · semaglutide 0.5 mg Dose studied: 0.5 mg56 weeksn = 6012018 |
|---|
No comparable result
3 randomized-trial results measure it in another way or another unit.
233 h·nmol/L
AUC0-24h,sema,SS · 3 mg oral semaglutide
Dose studied: 3 mg12 weeksn = 322024
No comparable result
2 randomized-trial results measure it in another way or another unit.
86.2%
Adverse events · semaglutide 0.5 mg
Dose studied: 0.5 mg56 weeksn = 6012018
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 12 trials, ranked by phase, then posted results and enrollment: 3 ongoing · source ClinicalTrials.gov (opens in a new tab)
Hoffmann-La Roche3,900 participants30 Sept 2026 to est. 22 Mar 2029
Obesity or Overweight
Hoffmann-La Roche2,500 participants30 Sept 2026 to est. 6 Oct 2030
Obesity or Overweight · Cardiovascular Disease
Hoffmann-La Roche600 participantsest. 30 Sept 2026 to est. 19 Jan 2029
Obesity or Overweight · Type 2 Diabetes
Top 3 of 663 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Novo Nordisk A/S17,604 participants24 Oct 2018 to 29 Jun 2023
Overweight · Obesity
Novo Nordisk A/S9,651 participants17 Jun 2019 to 23 Aug 2024
Diabetes Mellitus, Type 2
Novo Nordisk A/S3,533 participants17 Jun 2019 to 9 Jan 2024
Diabetes Mellitus, Type 2
124 more mention it but do not test it. They only measure it or name it in their text.